Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Industry News

Alcor Scientific’s iSED at the Winter Olympics

Feb. 9, 2018—Alcor Scientific announced its iSED Analyzer will be used by the laboratory at the Korean Medicine Center at the Pyeongchang 2018 Olympic Winter Games and Paralympic Winter Games. The iSED is a fully automated erythrocyte sedimentation rate analyzer that analyzes red blood cells to diagnose bacterial infections and inflammation as well as to monitor patients’ responses to medications such as chemotherapy or steroids. It provides a result in 20 seconds. South Korea’s Ministry of Health and Welfare and

Advanced Instruments single-sample osmometer

Feb. 8, 2018—Advanced Instruments announced its Osmo1 Single-Sample Micro-Osmometer. It is suited for clinical laboratories that directly draw and test small sample volumes and was designed specifically to improve efficiency and reduce sample turnaround time. The instrument measures the osmolality of body fluids, such as whole blood, serum, plasma, urine, feces, sweat, and tissue homogenate, using the freezing point depression method, which provides results in 90 seconds. Only 20 μL of sample is needed. Features of the Osmo1 include an

FDA: Rethink how diagnostics are regulated

Feb. 6, 2018—U.S. Food and Drug Administration commissioner Scott Gottlieb, MD, said we need to think differently about how we regulate diagnostics. “It’s been a little bit more challenging to define a pathway on how to get regulatory approval for the diagnostic at the same time you get regulatory approval for the drug, in part because a lot of these diagnostic tests have been promulgated as laboratory-developed tests, so they haven’t been brought through a traditional regulatory process,” Dr. Gottlieb

Houston Methodist cytopathology symposium

Jan. 15, 2018—The Department of Pathology and Genomic Medicine at Houston Methodist Hospital will be presenting a symposium, “Cytopathology and Small Biopsy: Update in the Texas Medical Center at Houston Methodist Hospital,” at the Houston Methodist Research Institute on Saturday, March 3. Through didactic lectures, panel discussions, and poster presentations, symposium attendees will learn how the new Bethesda System for Reporting Thyroid Cytopathology assesses the patient’s risk of malignancy regarding thyroid, salivary gland, and urinary tract cytology and small biopsies.

Perjeta OK’d for neoadjuvant use

Jan. 3, 2018—Genentech announced Dec. 20 the FDA’s approval of Perjeta (pertuzumab), in combination with Herceptin (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence. People should receive the adjuvant Perjeta-based regimen for one year (up to 18 cycles). The FDA has also converted the previously granted accelerated approval of the Perjeta-based regimen to full approval for neoadjuvant treatment of HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either

MARKETPLACE

TRENDING